Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Kantaro Biosciences, a joint venture with RenalytixAI (NASDAQ: RNLX), has received Emergency Use Authorization from the FDA for its COVID-SeroKlir antibody test kit. This semi-quantitative test detects IgG antibodies, demonstrating 98.8% sensitivity and 99.6% specificity. Manufactured in partnership with Bio-Techne Corporation (NASDAQ: TECH), production can reach up to 10 million tests monthly. The test aids in healthcare decision-making and assessing vaccine responses, underlining its importance in the ongoing fight against COVID-19.
Bio-Techne Corporation (NASDAQ: TECH) will be presenting at the Stephens Annual Investment Conference 2020 on November 17, 2020, at 3:00 p.m. EST. Chuck Kummeth, President and CEO, will lead the presentation, which will be available via a live webcast on the company's Investor Relations website.
In fiscal 2020, Bio-Techne generated approximately $739 million in net sales and employs over 2,300 people globally. The company specializes in developing high-quality proteins, diagnostic products, and genomic tools essential for scientific research and clinical diagnostics.
Bio-Techne Corporation (NASDAQ: TECH) has declared a quarterly dividend of $0.32 per share for the period ending September 30, 2020. This dividend is payable on November 27, 2020 to shareholders on record as of November 16, 2020. The company reported approximately $739 million in net sales for fiscal 2020 and employs over 2,300 people worldwide. Future dividends will be assessed quarterly by the Board of Directors.
Bio-Techne Corporation (NASDAQ:TECH) reported a robust first quarter for FY2021, ending September 30, with organic revenue growth of 10%, totaling $204.2 million. The GAAP EPS rose to $0.83 from $0.37 year-on-year, while adjusted EPS saw a 35% increase to $1.43. The Diagnostics and Genomics segment achieved 17% organic growth, bolstered by the launch of a new GMP manufacturing facility. Despite challenges from COVID-19, a positive long-term outlook is anticipated due to increased funding in life sciences.
Bio-Techne Corporation (NASDAQ: TECH) will have its CEO, Chuck Kummeth, present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 1:20 p.m. EST. Interested parties can access a live webcast through the Investor Relations website. Bio-Techne specializes in producing high-quality proteins and diagnostic tools used in biomedical research and clinical laboratories. In fiscal 2020, the company reported approximately $739 million in net sales and employs over 2,300 people globally.
Bio-Techne Corporation (NASDAQ: TECH) announced that CFO Jim Hippel will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 11, 2020, at 4:15 p.m. EST. Interested parties can access the live webcast through the company's Investor Relations website. Bio-Techne specializes in high-quality purified proteins, reagents, and diagnostic products, generating approximately $739 million in net sales in fiscal 2020. With over 2,300 employees, Bio-Techne continues to support scientific research, drug discovery, and clinical diagnostics.
Kantaro Biosciences has formed a two-year marketing and distribution agreement with EKF Diagnostics to provide its COVID-19 antibody tests, COVID-SeroKlir and COVID-SeroIndex, across Europe, with exclusive rights in the UK and Germany. The tests boast a CE Mark certification, demonstrating high sensitivity (97.8%) and specificity (99.6%) in detecting IgG antibodies. This partnership aims to enhance public health strategies and assist in assessing immunity amidst ongoing vaccination efforts. The technology is based on extensive research at the Mount Sinai Health System.
Kantaro Biosciences, in partnership with Bio-Techne Corporation, has secured CE marking for its COVID-SeroKlir and COVID-SeroIndex antibody test kits. These quantitative tests, now available to authorized clinical labs in the EU, provide crucial data about COVID-19 antibody presence and levels. COVID-SeroKlir demonstrates 97.8% sensitivity and 99.6% specificity, supporting both clinical and research applications. Kantaro aims to produce up to 10 million tests monthly, enhancing pandemic response efforts.
Bio-Techne Corporation (NASDAQ: TECH) launched the SARS-CoV-2 Multi-Antigen Serology Module for its Simple Western automated systems. This new assay detects human IgG antibodies against five SARS-CoV-2 antigens within three hours, processing up to 23 samples simultaneously. The module promises to enhance COVID-19 research by providing a detailed view of immune responses, offering quicker, reproducible results compared to traditional methods. Bio-Techne emphasizes its commitment to supporting vaccine developers and researchers with this advanced technology.
Summary not available.